Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 4,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ADM Clear all

Conditions: Breast Cancer
Interventions: cyclophosphamide, docetaxel, doxorubicin; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 5,351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 146
States / cities: Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 123 more

Conditions: Postoperative Delirium
Interventions: Alpha Optimization, Emergence from anesthesia with Dexmedetomidine; Procedure · Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 60 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Coronary Calcification, Endstage Renal Disease, Parathyroid Hormone
Interventions: Doxercalciferol administration, Doxercalciferol administered by 1-84-7-84; Drug
Lead sponsor: Southeast Renal Research Institute; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Cardiovascular Diseases, Heart Diseases, Obesity
Interventions: Single behavior intervention, Multiple behavior interventions, Control Intervention unrelated to weight; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 8 Years to 12 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prematurity, Cerebral Palsy
Interventions: NICU-based rehabilitation bundle, Standard of care; Other
Lead sponsor: University of Virginia; Other
Eligibility: Up to 33 Weeks
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Interstitial Cystitis, Painful Bladder Syndrome, Painful Bladder Syndrome (PBS)
Interventions: Clarix Flo, Placebo; Drug
Lead sponsor: David Sheyn; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Clevleand, Ohio

Conditions: Liver Cancer
Interventions: celecoxib, epirubicin hydrochloride; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anesthesia, Surgery With General Anesthesia, Noncardiac Surgery, Hypotension During Surgery, Acute Kidney Injury (AKI), Myocardial Injury After Noncardiac Surgery (MINS), Vasopressor
Interventions: Norepinephrine, Phenylephrine; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 18,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: San Francisco, California • College Park, Maryland • Ann Arbor, Michigan + 6 more

Conditions: Metastatic Cancer, Prostate Cancer
Interventions: Doxorubicin hydrochloride, Goserelin acetate, Leuprolide acetate, Zoledronic acid, orchiectomy, strontium chloride Sr; Drug · Procedure · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 4
States / cities: Orlando, Florida • Wichita, Kansas • Houston, Texas + 1 more

Conditions: Iron Deficiency Anemia
Interventions: Novel Medical Food; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Chronic Pain, Back Pain, Neck Pain, Self-management, Complementary Therapies
Interventions: Partners4Pain, Keys to Wellbeing; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Relationship Conflict, Relationship Distress
Interventions: Online Couple Intervention; Behavioral
Lead sponsor: OurRelationship; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 5
States / cities: Marietta, Georgia • Elkton, Maryland • Potsdam, New York + 2 more

Conditions: Pain, Postoperative, Femur Fracture
Interventions: Ropivacaine, Epinephrine, Morphine, 0.9% sodium chloride solution; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Breast Cancer, Metastatic Breast Cancer, Carcinoma of the Breast
Interventions: Survey (Participant), OpenEvidence CareConnect, Survey (Provider); Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Sleep Apnea, Atrial Fibrillation
Interventions: Continuous Positive Airway Pressure; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 317 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Aphasia
Interventions: Constant Therapy program; Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinson's Disease
Interventions: Structured physical activity, Health education; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tibial Fracture, Soft Tissue Injury
Interventions: Hyperbaric Oxygen Treatment; Other
Lead sponsor: Bayside Health; Government
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Concord, California

Conditions: Cyclic Vomiting Syndrome
Interventions: Not listed
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Breast Cancer, Metastasis
Interventions: General health survey questionnaires, PROMIS Cancer Function Brief 3D profile questionnaires, FACT-G questionnaires, Godin Leisure-Time Exercise Questionnaire, REAP-S questionnaires; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Breast Neoplasms, Neoplasm Metastasis
Interventions: peripheral blood progenitor cells carrying MDR1; Genetic
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: Ad5CMV-p53 gene, docetaxel, doxorubicin hydrochloride, conventional surgery, neoadjuvant therapy; Biological · Drug · Procedure
Lead sponsor: Introgen Therapeutics; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Interventions: Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W); Drug
Lead sponsor: QuantumLeap Healthcare Collaborative; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2031
U.S. locations: 42
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more

Conditions: Sarcoma
Interventions: Gemcitabine, Doxorubicin, Docetaxel, Nivolumab; Drug
Lead sponsor: Sarcoma Oncology Research Center, LLC; Other
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Santa Monica, California

Search by objective public record fields.

Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes

EEG-Guided Analgesic Titration During General Anesthesia to Improve Early Neurocognitive Recovery in Older Patients

Vitamin D and Carboxy PTH Fragments in Coronary Calcification

Behavior Change Family Counseling to Reduce Rate of Weight Gain in At-Risk Children

NEO Rehab for Infants at Risk of Cerebral Palsy

Amniotic Membrane Therapy for Interstitial Cystitis/Painful Bladder Syndrome

Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma

The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery

Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases

A Trial to Evaluate the Safety and Tolerability of a Novel Medical Food for Management of Iron Deficiency Anemia

Partners4Pain & Wellbeing: A Randomized Trial of Community Supported Complementary and Integrative Health Self-management for Back Pain

OurRelationship-S: A Digital Relationship-Strengthening Program for Couples Experiencing Substance Misuse

Efficacy of Peri-Incisional Multimodal Drug Injection Following Operative Management of Femur Fractures

Generative AI Patient Education Module for Breast Oncology

Influence of Sleep Apnea on Risk of Atrial Fibrillation

Functional Reorganization and Recovery of the Language and Domain-general Multiple Demand Systems in Aphasia

Telemedicine Intervention to Improve Cognitive Function

Hyperbaric Oxygen in Lower Leg Trauma

The Use of L-Carnitine And CoQ10 Supplements In the Treatment of Cyclic Vomiting Syndrome (CVS)

Assessing Functional Status Needs Via PRO Measures for Pts With Metastatic Breast Cancer

Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer

Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma